754 related articles for article (PubMed ID: 12735231)
1. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
2. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
Vincent GM
Annu Rev Med; 1998; 49():263-74. PubMed ID: 9509262
[TBL] [Abstract][Full Text] [Related]
3. The long QT syndromes: genetic basis and clinical implications.
Chiang CE; Roden DM
J Am Coll Cardiol; 2000 Jul; 36(1):1-12. PubMed ID: 10898405
[TBL] [Abstract][Full Text] [Related]
4. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.
Yang P; Kanki H; Drolet B; Yang T; Wei J; Viswanathan PC; Hohnloser SH; Shimizu W; Schwartz PJ; Stanton M; Murray KT; Norris K; George AL; Roden DM
Circulation; 2002 Apr; 105(16):1943-8. PubMed ID: 11997281
[TBL] [Abstract][Full Text] [Related]
5. [Genetic background predisposing the drug-induced long QT syndrome].
Horie M
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):401-7. PubMed ID: 12835534
[TBL] [Abstract][Full Text] [Related]
6. The inherited long QT syndrome: from ion channel to bedside.
Vincent GM; Timothy K; Fox J; Zhang L
Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
[TBL] [Abstract][Full Text] [Related]
7. [Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels].
Nakaya H
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):384-92. PubMed ID: 12835532
[TBL] [Abstract][Full Text] [Related]
8. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
Antzelevitch C
J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
[TBL] [Abstract][Full Text] [Related]
9. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Pearlstein R; Vaz R; Rampe D
J Med Chem; 2003 May; 46(11):2017-22. PubMed ID: 12747773
[No Abstract] [Full Text] [Related]
10. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.
Kuryshev YA; Brown AM; Wang L; Benedict CR; Rampe D
J Pharmacol Exp Ther; 2000 Nov; 295(2):614-20. PubMed ID: 11046096
[TBL] [Abstract][Full Text] [Related]
11. The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome.
Van Langen IM; Birnie E; Alders M; Jongbloed RJ; Le Marec H; Wilde AA
J Med Genet; 2003 Feb; 40(2):141-5. PubMed ID: 12566525
[No Abstract] [Full Text] [Related]
12. Modulation of HERG potassium channels by extracellular magnesium and quinidine.
Po SS; Wang DW; Yang IC; Johnson JP; Nie L; Bennett PB
J Cardiovasc Pharmacol; 1999 Feb; 33(2):181-5. PubMed ID: 10028924
[TBL] [Abstract][Full Text] [Related]
13. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Priori SG; Cantù F; Schwartz PJ
Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
15. KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population.
Liu W; Yang J; Hu D; Kang C; Li C; Zhang S; Li P; Chen Z; Qin X; Ying K; Li Y; Li Y; Li Z; Cheng X; Li L; Qi Y; Chen S; Wang Q
Hum Mutat; 2002 Dec; 20(6):475-6. PubMed ID: 12442276
[TBL] [Abstract][Full Text] [Related]
16. Novel KCNQ1 and HERG missense mutations in Dutch long-QT families.
Jongbloed RJ; Wilde AA; Geelen JL; Doevendans P; Schaap C; Van Langen I; van Tintelen JP; Cobben JM; Beaufort-Krol GC; Geraedts JP; Smeets HJ
Hum Mutat; 1999; 13(4):301-10. PubMed ID: 10220144
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system].
Chachin M; Kurachi Y
Nihon Yakurigaku Zasshi; 2002 Jun; 119(6):345-51. PubMed ID: 12089906
[TBL] [Abstract][Full Text] [Related]
18. C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence.
Berthet M; Denjoy I; Donger C; Demay L; Hammoude H; Klug D; Schulze-Bahr E; Richard P; Funke H; Schwartz K; Coumel P; Hainque B; Guicheney P
Circulation; 1999 Mar; 99(11):1464-70. PubMed ID: 10086971
[TBL] [Abstract][Full Text] [Related]
19. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.
Kang J; Chen XL; Wang L; Rampe D
J Pharmacol Exp Ther; 2001 Oct; 299(1):290-6. PubMed ID: 11561091
[TBL] [Abstract][Full Text] [Related]
20. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Witchel HJ; Hancox JC
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
